Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome
about
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancersDNA methylation changes in epithelial ovarian cancer histotypes.MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stabilityA Gene Gravity Model for the Evolution of Cancer Genomes: A Study of 3,000 Cancer Genomes across 9 Cancer TypesSpatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysisTITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data.The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples.Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.Tug-of-war between driver and passenger mutations in cancer and other adaptive processesTumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.Prognostic relevance of acquired uniparental disomy in serous ovarian cancer.A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.Integrated sequence and expression analysis of ovarian cancer structural variants underscores the importance of gene fusion regulationGenomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancerGlucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.Identification of recurrent focal copy number variations and their putative targeted driver genes in ovarian cancerSpecific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.Ovarian cancer: in search of better marker systems based on DNA repair defectsVCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancerDNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy.Genetic and molecular changes in ovarian cancer.Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patientsLatest research and treatment of advanced-stage epithelial ovarian cancer53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.Pathogenesis and heterogeneity of ovarian cancer.Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities.Current state of biomarkers in ovarian cancer prognosis.Genetic load makes cancer cells more sensitive to common drugs: evidence from Cancer Cell Line Encyclopedia.PARP-1 Expression Quantified by [18F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy.Recently identified drug resistance biomarkers in ovarian cancer.The Damaging Effect of Passenger Mutations on Cancer Progression.Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs
P2860
Q27006938-B1CC2277-4E10-4D21-959D-1957EBC78EC6Q27690722-8BDE48AA-F334-495F-BC2F-991ADF4F615FQ28240422-33C27F86-4001-4037-8921-D8D4B90E34BCQ28547803-BFE79ABF-BD38-4336-98CB-6FB5D94890ADQ28649475-5E96B547-F4E9-4C5A-BDF6-9AEEA66EE18BQ30838548-F1F73E4B-231D-42AA-AD99-30A747954AF7Q33574500-0CDFD26E-6A3B-42B4-BE63-5D027C7F6C99Q33874621-09E73760-9D20-4DB5-9275-99990D607CB3Q33955266-6653EDD6-2E42-4AC2-8A70-9532DB816CAEQ34409055-B0A3B599-842A-47C1-8FE4-ECF9D4A63859Q35050560-8190A98C-61A1-404D-A8F1-503448EDCC77Q35061331-FB99E9A3-11D4-44A1-8424-8B0E3C30061AQ35274995-0DF4D99C-5604-4590-960E-38BDF912D927Q35652910-B7F3A72D-D377-440A-9793-192F926F4AA2Q35692785-C09BBE80-2B51-4157-B945-970FABD80533Q35812762-9876EFB2-D849-4560-A84C-73CE596BA4D5Q35895214-768F01D6-B8CB-435C-8EA6-73231EA18FE0Q35961836-9DF1D5B0-74BE-45E1-B17D-CDD964739101Q36016635-B0AB2BA7-5FA0-470F-9498-3AE97F7D0081Q36031493-CC2DB986-8E48-4C3E-8BFB-26AC3CD53D7EQ36309603-C9A281C4-F3F7-4B4D-9036-240A98717BE3Q36589947-FCD47D43-670F-41B4-8EF3-A9B24FF93324Q36789013-7FDC1323-0948-4A38-987A-7B8CB777D674Q36889676-A40C8F8E-F6C3-4682-9CE1-A9BBD8B5AC21Q36956378-00E6DDE8-49E4-4EB8-9C40-E92BEA43D81DQ37094076-93CB1481-5541-492F-A0D5-E844EA93CC9BQ37156490-067F7FFF-518E-44C4-8441-3CEECE695F77Q37206348-D5A71925-F70A-490E-99B3-27C39C847FA2Q37469856-E934C452-A6E5-430A-AEC4-15C9D44DD457Q37546692-C111A1F6-F5A7-4842-8CA3-AE5F5931F90FQ37716509-05EA2709-020C-40C0-AF72-860F99572235Q38628964-CB330545-A8BF-4771-8619-B2DC05F27148Q38703264-33C32C21-0D4F-46C4-A04F-35B2709CE049Q38719698-2FF0EBE6-6F31-45CB-8607-03A60065E782Q38741073-7C6AD7E3-12A2-45A3-AD23-C7F2CC47A474Q38768283-FCBEC666-8DBC-4941-ACE6-94407471D9EBQ38848614-A0E88B06-9438-4374-A1EB-C0105CF7484EQ38852995-B99B2935-C8CB-468A-973C-6986104C081FQ39888234-AF0D96AC-B757-4BD3-A23F-B888E0639D5BQ41064551-C0B4BAEF-16D8-44D4-AC8F-698FCE946C18
P2860
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Profiles of genomic instabilit ...... ncer predict treatment outcome
@ast
Profiles of genomic instabilit ...... ncer predict treatment outcome
@en
Profiles of genomic instabilit ...... ncer predict treatment outcome
@nl
type
label
Profiles of genomic instabilit ...... ncer predict treatment outcome
@ast
Profiles of genomic instabilit ...... ncer predict treatment outcome
@en
Profiles of genomic instabilit ...... ncer predict treatment outcome
@nl
prefLabel
Profiles of genomic instabilit ...... ncer predict treatment outcome
@ast
Profiles of genomic instabilit ...... ncer predict treatment outcome
@en
Profiles of genomic instabilit ...... ncer predict treatment outcome
@nl
P2093
P2860
P50
P1476
Profiles of genomic instabilit ...... ncer predict treatment outcome
@en
P2093
Alexander Miron
Aquila Fatima
Dariush Etemadmoghadam
Gillian Mitchell
Helga B Salvesen
Huiying Piao
J Dirk Iglehart
Kathryn E Daniels
Matthew Schwede
P2860
P304
P356
10.1158/1078-0432.CCR-12-0857
P407
P50
P577
2012-08-21T00:00:00Z